Skip to content
Clinical Trials – home
PolandBack to Poland

Clinical trials in Bytom

51 clinical trials in Bytom, Poland. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Bytom at a glance
51
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

51 trials in Bytom

Open in trial search
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Takeda Development Center Americas Inc.
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Morf-057
  • Sponsor:Morphic Therapeutic Inc.
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Merck Healthcare KGaA
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ro7790121
  • Sponsor:F. Hoffmann-La Roche AG
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International
InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Peripheral Blood Mononuclear Cells Induced To An Early Apoptotic State
  • Sponsor:Enlivex Therapeutics Ltd.
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:ICOTROKINRA
  • Sponsor:Janssen Cilag International
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:ICOTROKINRA
  • Sponsor:Janssen Cilag International

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Bytom

What the registry says about research in the country

01 Autoimmune Disorders

Extensive research focusing on systemic lupus erythematosus treatments, including studies of innovative therapies like litifilimab and ianalumab. Multiple trials are evaluating new approaches to managing psoriatic arthritis and plaque psoriasis.

  • Systemic Lupus Erythematosus (SLE)
  • Psoriatic Arthritis
  • Plaque Psoriasis

Studies aim to improve disease management and patient outcomes through targeted therapies.

02 Inflammatory Conditions

Innovative research into inflammatory bowel diseases, with particular focus on Crohn's disease and ulcerative colitis treatments. Studies are evaluating novel compounds like obefazimod and NX-13 for therapeutic efficacy.

  • Crohn's Disease
  • Ulcerative Colitis
  • Polymyalgia Rheumatica

Trials emphasize both symptom management and disease modification approaches.

03 Musculoskeletal Disorders

Studies addressing knee osteoarthritis and related conditions, including innovative approaches combining weight management with joint health treatments. Research includes evaluation of new immunotherapy options.

  • Knee Osteoarthritis
  • Axial Spondyloarthritis
  • Rheumatoid Arthritis

Focus on developing treatments that improve mobility and reduce pain.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).